Video

How to slash colorectal surgery infection rates


 

REPORTING FROM THE ACS CLINICAL CONGRESS

A quality improvement project conducted at the Cleveland Clinic dropped the 30-day colorectal surgery infection rate from 11.8% to 6.6%, driven mostly by a reduction in deep organ space infections from 5.5% to 1.7%.

It was a remarkable finding that got the attention of attendees at the annual clinical congress of the American College of Surgeons. The Cleveland Clinic had been an outlier, in the wrong direction, compared with other centers, and administrators wanted a solution.

I. Emre Gorgun, MD, FACS, a colorectal surgeon and quality improvement officer at Cleveland Clinic, led the search for evidence-based interventions. Eventually, big changes were made to perioperative antibiotics, mechanical bowel prep, preop shower routines, and intraoperative procedures. The efforts paid off (Dis Colon Rectum. 2018 Jan;61[1]:89-98).

To help surgeons lower their own infection rates, Dr. Gorgun agreed to an interview at the meeting to explain exactly what was done.

There was resistance at first from surgeons who wanted to stick with their routines, but they came around once they were shown the data backing the changes. Eventually, “everyone was on board. We believe in this,” Dr. Gorgun said.

Recommended Reading

Adjuvant chemotherapy overused in young patients with colon cancer
MDedge Hematology and Oncology
Cardiovascular disease most common cause of death in CRC survivors
MDedge Hematology and Oncology
Disease site determines QOL, pain in recurrent rectal cancer
MDedge Hematology and Oncology
Transanal TME comparable to open, lap approaches to rectal cancer
MDedge Hematology and Oncology
Anal dysplasia surveillance called into question
MDedge Hematology and Oncology
NSAIDs remain a concern in colorectal ERAS protocols
MDedge Hematology and Oncology
Accuracy of colon cancer lymph node sampling influenced by location
MDedge Hematology and Oncology
No increased complication risk with delaying resection for LARC
MDedge Hematology and Oncology
Neoadjuvant-treated N2 rectal cancer linked to PCR failure
MDedge Hematology and Oncology
'Liver first' for select stage IV colon cancer gaining traction
MDedge Hematology and Oncology